Far upstream element-binding protein 1 is a prognostic biomarker and promotes nasopharyngeal carcinoma progression

Cell Death and Disease

Volumn 6, Issue 10, 2015, Pages

  Liu, Z H ^a,b   Hu, J L ^a   Liang, J Z ^a   Zhou, A J ^a   Li, M Z ^a   Yan, S M ^a   Zhang, X ^a   Gao, S ^a   Chen, L ^b   Zhong, Q ^a   Zeng, M S ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BINDING PROTEIN; FAR UPSTREAM ELEMENT BINDING PROTEIN 1; MESSENGER RNA; MYC PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DNA HELICASE; FUBP1 PROTEIN, HUMAN; MYC PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL POPULATION; CELL PROLIFERATION; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUSE; MTT ASSAY; NASOPHARYNX CARCINOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; DISEASE COURSE; DRUG RESISTANCE; ENZYMOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NASOPHARYNX TUMOR; NUDE MOUSE; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RADIATION TOLERANCE; SIDE POPULATION CELL; TUMOR CELL LINE; YOUNG ADULT;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; DNA HELICASES; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM TRANSPLANTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MYC; RADIATION TOLERANCE; SIDE-POPULATION CELLS; YOUNG ADULT;

EID: 84975222021     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.258     Document Type: Article

References (79)

1. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006; 15: 1765-1777.
2. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4: 757-768.
3. Kamran SC, Riaz N, Lee N. Nasopharyngeal carcinoma. Surg Oncol Clin N Am 2015; 24: 547-561.
4. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005; 365: 2041-2054.
5. Tsang CM, Deng W, Yip YL, Zeng MS, Lo KW, Tsao SW. Epstein-Barr virus infection and persistence in nasopharyngeal epithelial cells. Chin J Cancer 2014; 33: 549-555.
6. Lun SW, Cheung ST, Lo KW. Cancer stem-like cells in Epstein-Barr virus-associated nasopharyngeal carcinoma. Chin J Cancer 2014; 33: 529-538.
7. Lin X, Chen S, Xue X, Lu L, Zhu S, Li W et al. Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a potential vaccine and diagnostic agent. Cell Mol Immunol 2015; e-pub ahead of print 13 April 2015;
8. Stoker SD, Novalic Z, Wildeman MA, Huitema AD, Verkuijlen SA, Juwana H et al. Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2015; 141: 1845-1857.
9. Tsang CM, Tsao SW. The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Virol Sin 2015; 30: 107-121.
10. Sun X, Su S, Chen C, Han F, Zhao C, Xiao W et al. Long-term outcomes of intensitymodulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol 2014; 110: 398-403.
11. Oster SK, Ho CS, Soucie EL, Penn LZ. The myc oncogene: MarvelouslY Complex. Adv Cancer Res 2002; 84: 81-154.
12. Allday MJ. How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma? Semin Cancer Biol 2009; 19: 366-376.
13. Yang J, Deng X, Deng L, Gu H, Fan W, Cao Y. Telomerase activation by Epstein-Barr virus latent membrane protein 1 is associated with c-Myc expression in human nasopharyngeal epithelial cells. J Exp Clin Cancer Res 2004; 23: 495-506.
14. Fish K, Chen J, Longnecker R. Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma. Blood 2014; 123: 530-540.
15. Bieging KT, Amick AC, Longnecker R. Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis. Proc Natl Acad Sci USA 2009; 106: 17945-17950.
16. Sabo A, Kress TR, Pelizzola M, de Pretis S, Gorski MM, Tesi A et al. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature 2014; 511: 488-492.
17. Selmi A, de Saint-Jean M, Jallas AC, Garin E, Hogarty MD, Benard J et al. TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma. Cancer Lett 2015; 357: 412-418.
18. Wang HB, Liu GH, Zhang H, Xing S, Hu LJ, Zhao WF et al. Sp1 and c-Myc regulate transcription of BMI1 in nasopharyngeal carcinoma. FEBS J 2013; 280: 2929-2944.
19. Wang WJ, Wu SP, Liu JB, Shi YS, Huang X, Zhang QB et al. MYC regulation of CHK1 and CHK2 promotes radioresistance in a stem cell-like population of nasopharyngeal carcinoma cells. Cancer Res 2013; 73: 1219-1231.
20. Luo J, Xiao J, Tao Z, Li X. Detection of c-myc gene expression in nasopharyngeal carcinoma by nonradioactive in situ hybridization and immunohistochemistry. Chin Med J 1997; 110: 229-232.
21. Rydziel S, Delany AM, Canalis E. AU-rich elements in the collagenase 3 mRNA mediate stabilization of the transcript by cortisol in osteoblasts. J Biol Chem 2004; 279: 5397-5404.
22. Avigan MI, Strober B, Levens D. A far upstream element stimulates c-myc expression in undifferentiated leukemia cells. J Biol Chem 1990; 265: 18538-18545.
23. Duncan R, Bazar L, Michelotti G, Tomonaga T, Krutzsch H, Avigan M et al. A sequencespecific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes Dev 1994; 8: 465-480.
24. Huang PN, Lin JY, Locker N, Kung YA, Hung CT, Lin JY et al. Far upstream element binding protein 1 binds the internal ribosomal entry site of enterovirus 71 and enhances viral translation and viral growth. Nucleic Acids Res 2011; 39: 9633-9648.
25. Zheng Y, Miskimins WK. Far upstream element binding protein 1 activates translation of p27Kip1 mRNA through its internal ribosomal entry site. Int J Biochem Cell Biol 2011; 43: 1641-1648.
26. Chien HL, Liao CL, Lin YL. FUSE binding protein 1 interacts with untranslated regions of Japanese encephalitis virus RNA and negatively regulates viral replication. J Virol 2011; 85: 4698-4706.
27. Jang M, Park BC, Kang S, Chi SW, Cho S, Chung SJ et al. Far upstream element-binding protein-1, a novel caspase substrate, acts as a cross-talker between apoptosis and the c-myc oncogene. Oncogene 2009; 28: 1529-1536.
28. Chan AK, Pang JC, Chung NY, Li KK, Poon WS, Chan DT et al. Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors. Mod Pathol 2014; 27: 332-342.
29. Singer S, Malz M, Herpel E, Warth A, Bissinger M, Keith M et al. Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer. Cancer Res 2009; 69: 2234-2243.
30. Lasserre JP, Fack F, Revets D, Planchon S, Renaut J, Hoffmann L et al. Effects of the endocrine disruptors atrazine and PCB 153 on the protein expression of MCF-7 human cells. J Proteome Res 2009; 8: 5485-5496.
31. Xu SG, Yan PJ, Shao ZM. Differential proteomic analysis of a highly metastatic variant of human breast cancer cells using two-dimensional differential gel electrophoresis. J Cancer Res Clin Oncol 2010; 136: 1545-1556.
32. Malz M, Weber A, Singer S, Riehmer V, Bissinger M, Riener MO et al. Overexpression of far upstream element binding proteins: a mechanism regulating proliferation and migration in liver cancer cells. Hepatology 2009; 50: 1130-1139.
33. Zubaidah RM, Tan GS, Tan SB, Lim SG, Lin Q, Chung MC. 2-D DIGE profiling of hepatocellular carcinoma tissues identified isoforms of far upstream binding protein (FUBP) as novel candidates in liver carcinogenesis. Proteomics 2008; 8: 5086-5096.
34. Matsushita K, Tomonaga T, Kajiwara T, Shimada H, Itoga S, Hiwasa T et al. c-myc suppressor FBP-interacting repressor for cancer diagnosis and therapy. Front Biosci 2009; 14: 3401-3408.
35. Matsushita K, Tomonaga T, Shimada H, Shioya A, Higashi M, Matsubara H et al. An essential role of alternative splicing of c-myc suppressor FUSE-binding proteininteracting repressor in carcinogenesis. Cancer Res 2006; 66: 1409-1417.
36. Weber A, Kristiansen I, Johannsen M, Oelrich B, Scholmann K, Gunia S et al. The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer. BMC Cancer 2008; 8: 369.
37. Zhang J, Chen QM. Far upstream element binding protein 1: a commander of transcription, translation and beyond. Oncogene 2013; 32: 2907-2916.
38. Rabenhorst U, Beinoraviciute-Kellner R, Brezniceanu ML, Joos S, Devens F, Lichter P et al. Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth. Hepatology 2009; 50: 1121-1129.
39. Huynh T, Norris MD, Haber M, Henderson MJ. ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma. Front Oncol 2012; 2: 178.
40. Porro A, Haber M, Diolaiti D, Iraci N, Henderson M, Gherardi S et al. Direct and coordinate regulation of ATP-binding cassette transporter genes by Myc factors generates specific transcription signatures that significantly affect the chemoresistance phenotype of cancer cells. J Biol Chem 2010; 285: 19532-19543.
41. Wang Z, Xu Y, Meng X, Watari F, Liu H, Chen X. Suppression of c-Myc is involved in multi-walled carbon nanotubes' down-regulation of ATP-binding cassette transporters in human colon adenocarcinoma cells. Toxicol Appl Pharmacol 2015; 282: 42-51.
42. Hoe SL, Tan LP, Jamal J, Peh SC, Ng CC, Zhang WC et al. Evaluation of stem-like side population cells in a recurrent nasopharyngeal carcinoma cell line. Cancer Cell Int 2014; 14: 101.
43. Wang J, Guo LP, Chen LZ, Zeng YX, Lu SH. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res 2007; 67: 3716-3724.
44. Johnson PC, McAulay KA, Montgomery D, Lake A, Shield L, Gallagher A et al. Modeling HLA associations with EBV-positive and -negative Hodgkin lymphoma suggests distinct mechanisms in disease pathogenesis. Int J Cancer 2015; 137: 1066-1075.
45. Henriksson M, Luscher B. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res 1996; 68: 109-182.
46. Abba MC, Laguens RM, Dulout FN, Golijow CD. The c-myc activation in cervical carcinomas and HPV 16 infections. Mutat Res 2004; 557: 151-158.
47. Avet-Loiseau H, Gerson F, Magrangeas F, Minvielle S, Harousseau JL, Bataille R et al. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001; 98: 3082-3086.
48. Baker VV, Borst MP, Dixon D, Hatch KD, Shingleton HM, Miller D. c-myc amplification in ovarian cancer. Gynecol Oncol 1990; 38: 340-342.
49. Herms JW, von Loewenich FD, Behnke J, Markakis E, Kretzschmar HA. c-myc oncogene family expression in glioblastoma and survival. Surg Neurol 1999; 51: 536-542.
50. Miranda Peralta EI, Valles Ayoub Y, Hernandez Mendoza L, Rangel Ramirez LM, Castrejon Rojas A, Collazo-Jaloma J et al. [MYC protein and proteins antigenically related with MYC in acute lymphoblastic leukemia]. Rev Invest Clin 1991; 43: 139-145.
51. Treszl A, Adany R, Rakosy Z, Kardos L, Begany A, Gilde K et al. Extra copies of c-myc are more pronounced in nodular melanomas than in superficial spreading melanomas as revealed by fluorescence in situ hybridisation. Cytometry B Clin Cytom 2004; 60: 37-46.
52. Fan CS, Wong N, Leung SF, To KF, Lo KW, Lee SW et al. Frequent c-myc and Int-2 overrepresentations in nasopharyngeal carcinoma. Hum Pathol 2000; 31: 169-178.
53. Solares G, Blanco E, Pulgar S, Diago C, Ramos F. Carcinoid syndrome and intravenous cyproheptadine. Anaesthesia 1987; 42: 989-992.
54. Zhao Y, Pang TY, Wang Y, Wang S, Kang HX, Ding WB et al. LMP1 stimulates the transcription of eIF4E to promote the proliferation, migration and invasion of human nasopharyngeal carcinoma. FEBS J 2014; 281: 3004-3018.
55. Zhou W, Feng X, Ren C, Jiang X, Liu W, Huang W et al. Over-expression of BCAT1, a c-Myc target gene, induces cell proliferation, migration and invasion in nasopharyngeal carcinoma. Mol Cancer 2013; 12: 53.
56. Albihn A, Loven J, Ohlsson J, Osorio LM, Henriksson M. c-Myc-dependent etoposide-induced apoptosis involves activation of Bax and caspases, and PKCdelta signaling. J Cell Biochem 2006; 98: 1597-1614.
57. Bidwell GL 3rd, Raucher D. Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc. Biochem Pharmacol 2006; 71: 248-256.
58. Grassilli E, Ballabeni A, Maellaro E, Del Bello B, Helin K. Loss of MYC confers resistance to doxorubicin-induced apoptosis by preventing the activation of multiple serine protease- and caspase-mediated pathways. J Biol Chem 2004; 279: 21318-21326.
59. Penn LJ, Laufer EM, Land H. C-MYC: evidence for multiple regulatory functions. Semin Cancer Biol 1990; 1: 69-80.
60. He L, Liu J, Collins I, Sanford S, O'Connell B, Benham CJ et al. Loss of FBP function arrests cellular proliferation and extinguishes c-myc expression. EMBO J 2000; 19: 1034-1044.
61. Kim MJ, Park BJ, Kang YS, Kim HJ, Park JH, Kang JW et al. Downregulation of FUSE-binding protein and c-myc by tRNA synthetase cofactor p38 is required for lung cell differentiation. Nat Genet 2003; 34: 330-336.
62. Liu J, He L, Collins I, Ge H, Libutti D, Li J et al. The FBP interacting repressor targets TFIIH to inhibit activated transcription. Mol Cell 2000; 5: 331-341.
63. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol 2006; 16: 253-264.
64. Mateyak MK, Obaya AJ, Sedivy JM. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol 1999; 19: 4672-4683.
65. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001; 42: 1007-1017.
66. Higgins CF. ABC transporters: from microorganisms to man. Ann Rev Cell Biol 1992; 8: 67-113.
67. Liao WT, Wang HM, Li MZ, Song LB, Zhang L, Mai HQ et al. [Establishment of threedimensional culture models related to different stages of nasopharyngeal carcinogenesis]. Ai Zheng 2005; 24: 1317-1321.
68. Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu LJ et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelialmesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest 2009; 119: 3626-3636.
69. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 2006; 66: 6225-6232.
70. Peterson BR, Nelson BL. Nonkeratinizing undifferentiated nasopharyngeal carcinoma. Head Neck Pathol 2013; 7: 73-75.
71. Thompson L. World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Ear Nose Throat J 2006; 85: 74.
72. Li BS, Zuo QF, Zhao YL, Xiao B, Zhuang Y, Mao XH et al. MicroRNA-25 promotes gastric cancer migration, invasion and proliferation by directly targeting transducer of ERBB2, 1 and correlates with poor survival. Oncogene 2015; 34: 2556-2565.
73. Li Y, Zeng X, Wang S, Sun Y, Wang Z, Fan J et al. Inhibition of autophagy protects against PAMAM dendrimers-induced hepatotoxicity. Nanotoxicology 2015; 9: 344-355.
74. Zhang JP, Zhang H, Wang HB, Li YX, Liu GH, Xing S et al. Down-regulation of Sp1 suppresses cell proliferation, clonogenicity and the expressions of stem cell markers in nasopharyngeal carcinoma. J Transl Med 2014; 12: 222.
75. Xie F, Liu H, Zhu YH, Qin YR, Dai Y, Zeng T et al. Overexpression of GPR39 contributes to malignant development of human esophageal squamous cell carcinoma. BMC Cancer 2011; 11: 86.
76. Shirasaki T, Maruya S, Mizukami H, Kakehata S, Kurotaki H, Yagihashi S et al. Effects of small interfering RNA targeting thymidylate synthase on survival of ACC3 cells from salivary adenoid cystic carcinoma. BMC Cancer 2008; 8: 348.
77. Mehta G, Scheinman RI, Holers VM, Banda NK. A new approach for the treatment of arthritis in mice with a novel conjugate of an anti-C5aR1 antibody and C5 small interfering rNA. J Immunol 2015; 194: 5446-5454.
78. Jung HS, Rajasekaran N, Song SY, Kim YD, Hong S, Choi HJ et al. Human papillomavirus E6/E7-specific sirna potentiates the effect of radiotherapy for cervical cancer in vitro and in vivo. Int J Mol Sci 2015; 16: 12243-12260.
79. Chen S, Liu X, Gong W, Yang H, Luo D, Zuo X et al. Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts. Oncol Rep 2013; 29: 260-268.